Intarcia submits diabetes implant, gets $100M milestone

Intarcia Therapeutics Inc. (Boston, Mass.) submitted an NDA to FDA for ITCA 650 to treat Type II diabetes. The submission triggered a $100 million milestone payment to Intarcia under a 2015 royalty deal (see BioCentury, May 4, 2015).

In May, Intarcia said ITCA 650 met the primary endpoint in the Phase III FREEDOM-CVO cardiovascular outcomes trial in Type II diabetes. It had met the primary endpoints in three prior Phase III studies (see BioCentury Extra, May 6)...